Gilead Submits New Drug Application for Once-daily Single Tablet Regimen for HCV
Hepatitis C, News
Gilead Sciences submitted a regulatory new drug application (NDA) for its investigational, once-daily single tablet regimen of SOF/VEL/VOX (sofosbuvir, velpatasvir, and voxilaprevir) for the treatment of hepatitis C infection with the ... Read more